LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.570
+0.020 (1.29%)
Aug 29, 2025, 4:00 PM - Market closed

Company Description

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments.

The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies.

The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207.

LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.

LAVA Therapeutics N.V.
LAVA Therapeutics logo
CountryNetherlands
Founded2016
IPO DateMar 25, 2021
IndustryBiotechnology
SectorHealthcare
Employees34
CEOStephen Hurly

Contact Details

Address:
Yalelaan 62
Utrecht, 3584 CM
Netherlands
Phone31 85 016 3100
Websitelavatherapeutics.com

Stock Details

Ticker SymbolLVTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001840748
CUSIP NumberN51517105
ISIN NumberNL0015000AG6
SIC Code2834

Key Executives

NamePosition
Stephen Allen Hurly M.B.A., M.Sc.Chief Executive Officer, President and Executive Director
Fred M. Powell CPAChief Financial Officer
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.Chief Medical Officer
Oxana Polyakova Ph.D.Chief Scientific Officer
Amy Garabedian J.D.General Counsel and Corporate Secretary
Dr. Hans van der Vliet M.D., Ph.D.Head of Innovation
Dr. Ton Adang Ph.D.Chief Development Officer

Latest SEC Filings

DateTypeTitle
Aug 22, 2025PREM14AFiling
Aug 15, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 15, 2025SC 14D9Filing
Aug 15, 2025SC TO-TFiling
Aug 14, 20258-KCurrent Report
Aug 13, 202510-QQuarterly Report
Aug 4, 2025SC TO-CFiling
Aug 4, 2025SC14D9CFiling
Aug 4, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 4, 20258-KCurrent Report